Sun Pharma Advanced Research Company (SUNPHADV) is a pharma research and drug discovery company. Through a scheme of arrangement, it was formed on Feb. 28, 2007 when Sun Pharmaceutical Industries demerged its innovative research and development business into the company. The company is engaged in research projects for new molecules and new delivery systems, scientists, intellectual property, space and equipment. It has projects in drug development with current lead molecules in the allergy/inflammation area. Development of chemical delivery systems for drugs that have poor absorption characteristics is another area of research. In the new chemical entity segment, the antiallergic lead molecule, SUN 1334 H, is currently in phase II clinical trials in the US with phase III trials estimated to begin in 2008. The successful pre-clinical trials of SUN-S 461, an anti-inflammatory molecule, is now ready for further stages of clinical testing. SUN-G 44, a prodrug of the currently marketed drug gabapentin, is to enter further stages of preclinical and clinical testing. SUN-B09, a muscle relaxant, is currently in preclinical studies. The novel drug delivery systems of the company has a biodegradable polymer-based product for the treatment of cancers in preclinical trials; a nanoemulsion that offers 98% encapsulation of the medication; dry powder inhalation device to be launched by 2009; ANDAs based on the wrap matrix controlled release systems filed with the USFDA; the gastro retentive innovative device Baclofen ER, which has been approved for release in India and is being filed in the US; and Tobramycin and Dexa ophthalmic solution, used in the prophylaxis of infections after cataract surgery, passing through stages of regulatory approval. The registered office of the company is located at Sun Pharma Advanced Research Centre (SPARC), Akota Road, Akota, Vadodara-390020.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
